Pediatrics

Positive trial results for RSV infant treatment: Sanofi

French pharmaceutical giant Sanofi announced trial results on Friday that showed its preventative treatment for respiratory syncytial virus (RSV) reduced the rate of babies being hospitalized by more than 80 percent.

Diseases, Conditions, Syndromes

RSV: We finally have a vaccine for this deadly virus

The first vaccine against respiratory syncytial virus (RSV) has been approved by the US Food and Drug Administration. The vaccine, named Arexvy, will be given to people 60 years and older.

Diseases, Conditions, Syndromes

New immunotherapy treatment targets respiratory viral infections

A University of Central Florida College of Medicine researcher has developed a new, more precise treatment for a major cause of illness around the world each year—acute respiratory viral infections.

Diseases, Conditions, Syndromes

FDA approves first RSV vaccine

The first vaccine for respiratory syncytial virus (RSV) has been approved by the U.S. Food and Drug Administration for use in seniors aged 60 and older.

page 12 from 40